23andMe, a popular direct-to-consumer genetic testing company, made headlines after its CEO pledged to help reunite the more than 2,300 children separated from their parents at the U.S.’s southern ...

Anne Wojcicki is set to regain control of 23andMe after a $305 million bid from a nonprofit she controls topped Regeneron Pharmaceuticals’ offer for the DNA-testing company in a bankruptcy auction.

Genetic testing company 23andMe laid off 100 employees on Jan. 23 due to decreasing sales of its direct-to-consumer DNA test kits, CNBC reports. The layoffs, which affect about 14 percent of the ...

23andMe, which sold saliva collection kits to consumers wanting insight into their genetic background, filed for bankruptcy in March 2025. The company has now agreed to sell its data bank to Regeneron ...

Regeneron Pharmaceuticals will acquire 23andMe's assets for $256 million, both companies said. 23andMe filed for Chapter 11 bankruptcy earlier this year. The DNA testing company has faced major ...

Tarrytown-based Regeneron would acquire 23andMe for $256 million under the deal that is pending approval by bankruptcy court and regulators. New York-based biotech giant Regeneron Pharmaceuticals ...

Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe for $256 million through a bankruptcy auction, the companies said Monday. Regeneron said it will comply with 23andMe’s privacy ...

Genetics testing company 23andMe on Monday announced a deal to be acquired by biotechnology company Regeneron. The $256 million sale is subject to court oversight, and still needs approval. The sale ...

Bankrupt genetic-testing firm 23andMe agreed to sell its data bank, which once contained DNA samples from about 15 million people, to the drug developer Regeneron Pharmaceuticals for $256 million. The ...